Raymond P Goodrich

Summary

Publications

  1. doi Toxicity testing of a novel riboflavin-based technology for pathogen reduction and white blood cell inactivation
    Heather L Reddy
    Navigant Biotechnologies, Inc, Lakewood, CO, USA
    Transfus Med Rev 22:133-53. 2008
  2. doi Evaluation of potential immune response and in vivo survival of riboflavin-ultraviolet light-treated red blood cells in baboons
    Raymond P Goodrich
    Navigant Biotechnologies, Lakewood, Colorado 80227, USA
    Transfusion 49:64-74. 2009
  3. ncbi The Mirasol PRT system for pathogen reduction of platelets and plasma: an overview of current status and future trends
    Raymond P Goodrich
    Navigant Biotechnologies Inc, Lakewood, CO 80215, USA
    Transfus Apher Sci 35:5-17. 2006
  4. ncbi Correlation of in vitro platelet quality measurements with in vivo platelet viability in human subjects
    Raymond P Goodrich
    Navigant Biotechnologies, Inc, Lakewood, CO 80215, USA
    Vox Sang 90:279-85. 2006
  5. doi Quality of proteins in riboflavin and UV light-treated FFP during 1 year of storage at -18°C
    Anna Ettinger
    CaridianBCT Biotechnologies, LLC, Lakewood, CO 80215, USA
    Transfus Apher Sci 46:15-8. 2012
  6. doi Preparation of cryoprecipitate from riboflavin and UV light-treated plasma
    Anna Ettinger
    CaridianBCT Biotechnologies, LLC, Lakewood, CO, USA
    Transfus Apher Sci 46:153-8. 2012
  7. doi Development of a riboflavin and ultraviolet light-based device to treat whole blood
    Heather L Reddy
    Terumo BCT Biotechnologies, LLC, Lakewood, Colorado, USA
    Transfusion 53:131S-136S. 2013
  8. doi Design and development of a method for the reduction of infectious pathogen load and inactivation of white blood cells in whole blood products
    Raymond P Goodrich
    CaridianBCT Biotechnologies LLC, 1215 Quail Street, Lakewood, CO 80215, USA
    Biologicals 38:20-30. 2010
  9. ncbi Platelet glycolytic flux increases stimulated by ultraviolet-induced stress is not the direct cause of platelet morphology and activation changes: possible implications for the role of glucose in platelet storage
    Junzhi Li
    Navigant Biotechnologies, Inc, Lakewood, CO 80215, USA
    Transfusion 45:1750-8. 2005
  10. ncbi Evaluation of platelet mitochondria integrity after treatment with Mirasol pathogen reduction technology
    Junzhi Li
    Navigant Biotechnologies, Inc, Lakewood, Colorado 80215, USA
    Transfusion 45:920-6. 2005

Collaborators

Detail Information

Publications20

  1. doi Toxicity testing of a novel riboflavin-based technology for pathogen reduction and white blood cell inactivation
    Heather L Reddy
    Navigant Biotechnologies, Inc, Lakewood, CO, USA
    Transfus Med Rev 22:133-53. 2008
    ..The possible presence of leachable or extractable compounds (from the disposable set) was evaluated with novel assays for measuring these compounds in blood. No treatment-related toxicity was observed in any of the studies...
  2. doi Evaluation of potential immune response and in vivo survival of riboflavin-ultraviolet light-treated red blood cells in baboons
    Raymond P Goodrich
    Navigant Biotechnologies, Lakewood, Colorado 80227, USA
    Transfusion 49:64-74. 2009
    ..This study evaluated the hypothesis that there is no immune response to riboflavin-and-ultraviolet [UV]-light-treated red blood cells (RBCs), as observed by serology and by survival of RBCs in circulation...
  3. ncbi The Mirasol PRT system for pathogen reduction of platelets and plasma: an overview of current status and future trends
    Raymond P Goodrich
    Navigant Biotechnologies Inc, Lakewood, CO 80215, USA
    Transfus Apher Sci 35:5-17. 2006
    ..The Mirasol PRT process is based on riboflavin photochemistry. This manuscript reviews current progress and future trends...
  4. ncbi Correlation of in vitro platelet quality measurements with in vivo platelet viability in human subjects
    Raymond P Goodrich
    Navigant Biotechnologies, Inc, Lakewood, CO 80215, USA
    Vox Sang 90:279-85. 2006
    ....
  5. doi Quality of proteins in riboflavin and UV light-treated FFP during 1 year of storage at -18°C
    Anna Ettinger
    CaridianBCT Biotechnologies, LLC, Lakewood, CO 80215, USA
    Transfus Apher Sci 46:15-8. 2012
    ..Comparisons were made to paired, untreated controls after 6 months and 1 year of storage...
  6. doi Preparation of cryoprecipitate from riboflavin and UV light-treated plasma
    Anna Ettinger
    CaridianBCT Biotechnologies, LLC, Lakewood, CO, USA
    Transfus Apher Sci 46:153-8. 2012
    ....
  7. doi Development of a riboflavin and ultraviolet light-based device to treat whole blood
    Heather L Reddy
    Terumo BCT Biotechnologies, LLC, Lakewood, Colorado, USA
    Transfusion 53:131S-136S. 2013
    ..Such a system is in development and utilizes riboflavin and ultraviolet light to provide pathogen reduction and WBC inactivation...
  8. doi Design and development of a method for the reduction of infectious pathogen load and inactivation of white blood cells in whole blood products
    Raymond P Goodrich
    CaridianBCT Biotechnologies LLC, 1215 Quail Street, Lakewood, CO 80215, USA
    Biologicals 38:20-30. 2010
    ..This manuscript describes development efforts using a photochemical PRT method employing riboflavin and UV-Light (Mirasol PRT)...
  9. ncbi Platelet glycolytic flux increases stimulated by ultraviolet-induced stress is not the direct cause of platelet morphology and activation changes: possible implications for the role of glucose in platelet storage
    Junzhi Li
    Navigant Biotechnologies, Inc, Lakewood, CO 80215, USA
    Transfusion 45:1750-8. 2005
    ..Stress-enhanced platelet (PLT) storage lesions include increased glycolysis, discoid-to-sphere morphology change, and spontaneous PLT activation. It is not clear if reduction in glycolysis can alleviate storage lesion development...
  10. ncbi Evaluation of platelet mitochondria integrity after treatment with Mirasol pathogen reduction technology
    Junzhi Li
    Navigant Biotechnologies, Inc, Lakewood, Colorado 80215, USA
    Transfusion 45:920-6. 2005
    ..Increased glycolytic flux could result from damage to mitochondria and/or increased ATP consumption...
  11. doi Protein stability of previously frozen plasma, riboflavin and UV light-treated, refrozen and stored for up to 2 years at -30 °C
    Anna Ettinger
    CaridianBCT Biotechnologies, LLC, Lakewood, CO 80215, United States
    Transfus Apher Sci 44:25-31. 2011
    ..The objective of this study was to evaluate the in vitro protein quality of previously frozen FFP, thawed, Mirasol-treated and refrozen for a final storage period of up to 2 years at -30 °C...
  12. ncbi Photochemical inactivation of selected viruses and bacteria in platelet concentrates using riboflavin and light
    Patrick H Ruane
    Navigant Biotechnologies, Lakewood, Colorado 80215, USA
    Transfusion 44:877-85. 2004
    ..A medical device is being developed for the reduction of pathogens in PLT concentrates (PCs). The device uses broadband UV light and the compound riboflavin (vitamin B(2))...
  13. doi A laboratory comparison of pathogen reduction technology treatment and culture of platelet products for addressing bacterial contamination concerns
    Raymond P Goodrich
    CaridianBCT Biotechnologies LLC, Lakewood, CO 80215, USA
    Transfusion 49:1205-16. 2009
    ..Concerns over the risk of bacterial contamination of platelet products have led to implementation of bacteria culture and other screening methods. New approaches for dealing with this issue have also been proposed...
  14. ncbi Riboflavin and UV-light based pathogen reduction: extent and consequence of DNA damage at the molecular level
    Vijay Kumar
    Navigant Biotechnologies, 1215 Quail Street, Lakewood, CO 80215, USA
    Photochem Photobiol 80:15-21. 2004
    ..These data also suggest that the type and extent of damage to DNA for virus in the presence of RB and light make it less likely to be repaired by normal repair pathways available in host cells...
  15. doi White blood cell inactivation after treatment with riboflavin and ultraviolet light
    Susanne Marschner
    CaridianBCT Biotechnologies, LLC, Lakewood, Colorado 80215, USA
    Transfusion 50:2489-98. 2010
    ..Data from in vitro studies and this clinical trial suggest that PRT treatment may be as effective as gamma irradiation in preventing TA-GVHD and more effective than leukoreduction in preventing alloimmunization...
  16. ncbi Separation, identification and quantification of riboflavin and its photoproducts in blood products using high-performance liquid chromatography with fluorescence detection: a method to support pathogen reduction technology
    Christopher C Hardwick
    Navigant Biotechnologies Inc, Lakewood, CO 80215, USA
    Photochem Photobiol 80:609-15. 2004
    ..Additional photoproducts could also be identified and quantified using this method. The presence of these agents in normal, untreated blood suggests that their presence in blood is ubiquitous...
  17. doi Defining "adequate" pathogen reduction performance for transfused blood components
    Raymond P Goodrich
    CaridianBCT Biotechnologies, LLC, Lakewood, Colorado 80215, USA
    Transfusion 50:1827-37. 2010
    ....
  18. ncbi Efficacy of apheresis platelets treated with riboflavin and ultraviolet light for pathogen reduction
    James P AuBuchon
    Dartmouth Hitchcock Medical Center, Lebanon, New Hampshire, USA
    Transfusion 45:1335-41. 2005
    ..The efficacy of apheresis PLTs treated with riboflavin (vitamin B2) plus ultraviolet (UV) light (Mirasol, Navigant Biotechnologies) was investigated in a single-blind, crossover study in comparison to untreated PLTs...
  19. ncbi Treatment with riboflavin and ultraviolet light prevents alloimmunization to platelet transfusions and cardiac transplants
    Hiroshi Asano
    Department of Pathology, John Hopkins Medical Institutions, Baltimore, MD 21205 2196, USA
    Transplantation 84:1174-82. 2007
    ..The current study evaluated the ability of Mirasol treatment to prevent alloimmunization by platelet transfusions in rats...
  20. ncbi Comparison of computerized formulae for determination of platelet recovery and survival
    James P AuBuchon
    Transfusion 45:1237-9. 2005